Results 11 to 20 of about 3,645,426 (307)

The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy [PDF]

, 2021
Cancer immunotherapy harnesses the immune system by targeting tumor cells that express antigens recognized by immune system cells, thus leading to tumor rejection.
Narges Baluch, Neda Ashayeri, Qorri, Bessi, Kumar, Sushil, Das, Bikul, Cheng, Hai-Ling Margaret, Manpreet Sambi, Szewczuk, Myron R., Sambi, Manpreet, Hai-Ling Margaret Cheng, Ashayeri, Neda, Bikul Das, Myron R. Szewczuk, Herman Yeger, Bessi Qorri, Sushil Kumar, Yeger, Herman, Baluch, Narges, Mokhtari, Reza Bayat, Reza Bayat Mokhtari   +19 more
core   +1 more source

The inter-link of ageing, cancer and immunity: findings from real-world retrospective study

Immunity & Ageing, 2023
Background Although the concept of declined immune function associated with cancer has been accepted extensively, real-world clinical studies focusing on analysis of the peripheral blood immune changes underlying ageing, immunity and cancer are scarce ...
Xiaomin Fu, Peng Qin, Fanghui Li, Huifang Zhu, Hongqin You, Yong Zhang, Benling Xu, Tiepeng Li, Fang Zhang, Lu Han, Lingdi Zhao, Baozhen Ma, Zibing Wang, Quanli Gao   +13 more
doaj   +1 more source

Exhaustion of CAR T cells: potential causes and solutions

Journal of Translational Medicine, 2022
Chimeric antigen receptor (CAR) T cell therapy has attracted attention for its promising therapeutic effects on hematological malignancies. However, there are problems such as relapse during long-term follow-up and limited effect on solid tumors with ...
Taku Kouro, Hidetomo Himuro, Tetsuro Sasada   +2 more
doaj   +1 more source

Recent Advances and Challenges in Cancer Immunotherapy

, 2022
SIMPLE SUMMARY: Immunotherapy helps a person’s immune system to target tumor cells. Recent advances in cancer immunotherapy, including immune checkpoint inhibition, chimeric antigen receptor T-cell therapy and cancer vaccination, have changed the ...
Yiping Yang, Peterson, Chelsea, Denlinger, Nathan, Chelsea Peterson, Nathan Denlinger, Yang, Yiping   +5 more
core   +1 more source

Advancing Cancer Immunotherapy: From Molecular Mechanisms to Clinical Applications

, 2023
In recent years, cancer immunotherapy research has made remarkable progress, completely transforming the cancer treatment landscape [...
Timothy Starr, Subbaya Subramanian, Xianda Zhao   +2 more
core   +1 more source

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Journal for ImmunoTherapy of Cancer, 2019
.
Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz Jr, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau   +40 more
doaj   +1 more source

Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity

OncoImmunology, 2021
Cancer-associated fibroblasts (CAFs) and hypoxia are central players in the complex process of tumor cell-stroma interaction and are involved in the alteration of the anti-tumor immune response by impacting both cancer and immune cell populations ...
Linda Ziani, Stéphanie Buart, Salem Chouaib, Jerome Thiery   +3 more
doaj   +1 more source

Engineering IL-4 resistant proinflammatory human myeloid cells for cancer immunotherapy. [PDF]

Mol Oncol
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Barberi T, Friedman AD.
europepmc   +2 more sources

Immunotherapy of lung cancer: An update [PDF]

, 2006
In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Hatz, R. A., Jauch, Karl-Walter, van den Engel, N.K., Fox, B.A., Grützner, S., Hatz, R.A., Rüttinger, D., Fox, B. A., Jauch, K.-W., Winter, H., van den Engel, N. K., Schendel, D. J., Pohlac, H., Pohla, H., Schlemmer, M., Schendel, D.J.   +15 more
core   +1 more source

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Journal for ImmunoTherapy of Cancer, 2019
Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor ...
Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau   +40 more
doaj   +1 more source